专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007150075A2 COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE 审中-公开
标题翻译：包含纳米颗粒糊精和受控释放氢化物的组合物
公开(公告)号：WO2007150075A2
公开(公告)日：2007-12-27
申请号：PCT/US2007/072054
申请日：2007-06-25
申请人： ELAN PHARMA INTERNATIONAL LIMITED , STARK, Paul , DEVANE, John , FANNING, Niall , LIVERSIDGE, Gary , JENKINS, Scott , SINGH-REKHI, Gurvinder
发明人： STARK, Paul , DEVANE, John , FANNING, Niall , LIVERSIDGE, Gary , JENKINS, Scott , SINGH-REKHI, Gurvinder
IPC分类号： A61K31/485
CPC分类号： A61K31/485 , A61K9/107 , A61K9/145 , A61K9/146 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K9/5138 , A61K9/5161
摘要： The invention relates to a compositions comprising a nanoparticulate meloxicam composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone - comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.
摘要翻译：本发明涉及一种组合物，其包含与多颗粒改性释放氢可酮组合物组合的纳米微粒美洛昔康组合物，其在给予患者时以双峰或多峰方式递送氢可酮。多微粒改性组合物包含第一组分和至少一个后续组分; 所述第一组分包含第一群含氢可酮的颗粒，所述至少一个后续组分包含第二组含氢可酮的颗粒，其中所述组分的组合表现出双峰或多峰释放曲线。本发明还涉及包含这种组合组合物的固体口服剂型。

2. 发明申请

WO2007106111A2 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING NILVADIPINE 审中-公开
标题翻译：包含NILVADIPINE的纳米颗粒和受控释放组合物
公开(公告)号：WO2007106111A2
公开(公告)日：2007-09-20
申请号：PCT/US2006/025803
申请日：2006-06-30
申请人： ELAN PHARMA INTERNATIONAL LIMITED , DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
发明人： DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
CPC分类号： A61K9/146 , A61K9/145 , A61K9/1676 , A61K9/2054 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K31/44
摘要： The present invention provides a composition comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, useful in the treatment and prevention of hypertension or related cardiovascular disorders. In one embodiment, the composition comprises nanoparticulate particles comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of hypertension or related cardiovascular disorders.
摘要翻译：本发明提供了包含尼伐地平或其盐，衍生物，前药或多晶型物的组合物，其可用于治疗和预防高血压或相关心血管疾病。在一个实施方案中，组合物包含包含尼伐地平或其盐，衍生物，前药或多晶型物和至少一种表面稳定剂的纳米颗粒颗粒。纳米颗粒具有小于约2000nm的有效平均粒度。在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送尼伐地平或其盐，衍生物，前药或多晶型物。本发明还涉及含有这种组合物的剂型，以及治疗和预防高血压或相关心血管疾病的方法。

3. 发明申请

WO2007053197A2 NANOPARTICULATE ACETAMINOPHEN FORMULATIONS 审中-公开
标题翻译：纳米颗粒醋氨酚制剂
公开(公告)号：WO2007053197A2
公开(公告)日：2007-05-10
申请号：PCT/US2006/021656
申请日：2006-06-05
申请人： ELAN PHARMA INTERNATIONAL, LIMITED , JENKINS, Scott , LIVERSIDGE, Gary, G.
发明人： JENKINS, Scott , LIVERSIDGE, Gary, G.
CPC分类号： A61K9/145 , A61K9/146 , A61K31/167
摘要： The invention is directed to compositions comprising a nanoparticulate acetaminophen composition, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate acetaminophen particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of aches and pain, and in the reduction of fever and related conditions.
摘要翻译：本发明涉及具有改善的生物利用度的包含纳米微粒对乙酰氨基酚组合物或其盐或衍生物的组合物。组合物的纳米微粒对乙酰氨基酚颗粒具有小于约2000nm的有效平均粒径，并且可用于治疗疼痛和疼痛，以及降低发热和相关疾病。

4. 发明申请

WO2006133045A1 NANOPARTICULATE BENIDIPINE COMPOSITIONS 审中-公开
标题翻译：纳米颗粒组合物
公开(公告)号：WO2006133045A1
公开(公告)日：2006-12-14
申请号：PCT/US2006/021655
申请日：2006-06-05
申请人： ELAN PHARMA INTERNATIONAL, LIMITED , LIVERSIDGE, Gary, G. , JENKINS, Scott
发明人： LIVERSIDGE, Gary, G. , JENKINS, Scott
IPC分类号： A61K31/4545 , A61P9/10 , A61P9/12
CPC分类号： A61K9/145 , A61K9/146 , A61K31/4545
摘要： The present invention relates to nanoparticulate benidipine compositions having improved bioavailability. The compositions comprise benidipine particles having an effective average particle size of less than about 2000 nm and may be useful in the prevention and treatment of hypertension, renal parenchymal hypertension and angina pectoris.
摘要翻译：本发明涉及具有改善的生物利用度的纳米微粒贝尼迪定组合物。组合物包含具有小于约2000nm的有效平均粒度的贝尼地平颗粒，并且可用于预防和治疗高血压，肾实质性高血压和心绞痛。

5. 发明申请

WO2006102117A1 NANOPARTICULATE BIPHOSPHONATE COMPOSITIONS 审中-公开
标题翻译：纳米磷酸二苯酯组合物
公开(公告)号：WO2006102117A1
公开(公告)日：2006-09-28
申请号：PCT/US2006/009791
申请日：2006-03-17
申请人： ELAN PHARMA INTERNATIONAL LIMITED , LIVERSIDGE, Gary , JENKINS, Scott
发明人： LIVERSIDGE, Gary , JENKINS, Scott
IPC分类号： A61K9/51 , A61K9/14 , A61K47/02 , A61P19/08 , A61P9/10 , A61K31/663
CPC分类号： A61K9/146 , A61K9/0019 , A61K9/145 , A61K31/66 , A61K31/663 , Y10S514/824
摘要： Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal.
摘要翻译：描述了具有小于2000nm的有效平均粒度的纳米颗粒二膦酸盐组合物。该组合物可用于治疗哺乳动物的骨吸收。

6. 发明申请

WO2006088864A1 CONTROLLED RELEASE COMPOSITIONS COMPRISING LEVETIRACETAM 审中-公开
标题翻译：包含LEVETIRACETAM的受控释放组合物
公开(公告)号：WO2006088864A1
公开(公告)日：2006-08-24
申请号：PCT/US2006/005167
申请日：2006-02-14
申请人： ELAN PHARMA INTERNATIONAL LIMITED , JENKINS, Scott , LIVERSIDGE, Gary
发明人： JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/22
CPC分类号： A61K9/2077
摘要： The invention relates to a controlled release composition comprising levetiracetam for the treatment of epilepsy. The controlled release composition comprises an immediate release component and a modified release component or formulation. The immediate release component comprises a first population of levetiracetam and the modified release component or formulation preferably comprises a second population of levetiracetam and a controlled release constituent. The modified release formulation is preferably in the form of an erodable formulation, a diffusion controlled formulation or an osmotic controlled formulation. The combination of the immediate release component and the modified release component or formulation in operation deliver the active ingredient in a pulsed or bimodal manner.
摘要翻译：本发明涉及包含用于治疗癫痫的左乙拉西坦的控释组合物。控释组合物包含立即释放组分和改性释放组分或制剂。立即释放组分包含左乙拉西坦的第一群体，并且改性释放组分或制剂优选包含第二群左乙拉西坦和控释组分。改性释放制剂优选为可侵蚀制剂，扩散控制制剂或渗透控制制剂的形式。立即释放组分和操作中的调节释放组分或制剂的组合以脉冲或双峰方式递送活性成分。

7. 发明申请

WO2011146583A2 NANOPARTICULATE CINACALCET FORMULATIONS 审中-公开
标题翻译： NANOPARTICULATE CINACALCET配方
公开(公告)号：WO2011146583A2
公开(公告)日：2011-11-24
申请号：PCT/US2011/036949
申请日：2011-05-18
申请人： ELAN PHARMA INTERNATIONAL LIMITED , NEVILLE, Deborah , JENKINS, Scott , MANSER, David
发明人： NEVILLE, Deborah , JENKINS, Scott , MANSER, David
IPC分类号： A61K9/14 , A61K31/137
CPC分类号： A61K31/137 , A61K9/10 , A61K9/1605 , A61K9/5138 , A61K9/5146 , A61K9/5161 , A61K9/5192
摘要： The invention is directed to compositions comprising stable nanoparticulate cinacalcet or a salt thereof. The composition can exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions. The invention also encompasses methods of making and using such compositions.
摘要翻译：本发明涉及包含稳定的纳米颗粒西那卡塞或其盐的组合物。与空腹条件相比，组合物可以表现出改善的溶解速率，改善的生物利用度和减少的进食口服给药时的差异。本发明还包括制备和使用这些组合物的方法。

8. 发明申请

WO2008010784A1 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING A CEPHALOSPORIN 审中-公开
标题翻译：包含CEPHOROSPORIN的纳米颗粒和受控释放组合物
公开(公告)号：WO2008010784A1
公开(公告)日：2008-01-24
申请号：PCT/US2006/018835
申请日：2006-05-16
申请人： ELAN PHARMA INTERNATIONAL LIMITED , DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
发明人： DEVANE, John , STARK, Paul , FANNING, Niall , REKHI, Gurvinder , JENKINS, Scott , LIVERSIDGE, Gary
IPC分类号： A61K9/64
CPC分类号： A61K9/14 , A61K9/1676 , A61K9/5078
摘要： The present invention is directed to compositions comprising a nanoparticulate antibiotic having improved bioavailability. Preferably, the antibiotic comprises nanoparticulate cephalosporin particles with an effective average particle size of less than about 2000 nm and are useful in the treatment of bacterial infection. The invention also relates to a controlled release composition comprising a cephalosporin or a nanoparticulate cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The nanoparticulate cephalosporin particles may be formulated as a controlled release drug delivery system whereby the particles are coated one or more times with one or more natural or synthetic hydrophilic or hydrophobic polymer coating materials or dispersed throughout a natural or synthetic hydrophilic and/or hydrophobic polymer matrix.
摘要翻译：本发明涉及包含具有改善的生物利用度的纳米颗粒抗生素的组合物。优选地，抗生素包含有效平均粒度小于约2000nm的纳米微粒头孢菌素颗粒，并且可用于治疗细菌感染。本发明还涉及包含头孢菌素或纳米微粒头孢菌素的控释组合物，其在操作中以脉冲或双峰方式递送药物用于治疗细菌感染。纳米颗粒头孢菌素颗粒可以配制成控释药物递送系统，由此颗粒用一种或多种天然或合成的亲水或疏水性聚合物涂层材料涂覆一次或多次，或分散在整个天然或合成的亲水和/或疏水性聚合物基质中。

9. 发明申请

WO2006135689A2 NANOPARTICULATE EBASTINE FORMULATIONS 审中-公开
标题翻译：纳米颗粒EBASTINE配方
公开(公告)号：WO2006135689A2
公开(公告)日：2006-12-21
申请号：PCT/US2006/022330
申请日：2006-06-08
申请人： ELAN PHARMA INTERNATIONAL, LIMITED , LIVERSIDGE, Gary, G. , JENKINS, Scott
发明人： LIVERSIDGE, Gary, G. , JENKINS, Scott
CPC分类号： A61K9/14 , A61K9/145 , A61K9/146 , A61K31/445 , A61K47/186
摘要： The invention is directed to compositions comprising at least one nanoparticulate H 1-histamine receptor antagonist, such as ebastine or a salt or derivative thereof, having improved dissolution rate providing a faster onset of drug availability. The nanoparticulate H1-histamine receptor antagonist particles, such as ebastine, have an effective average particle size of less than about 2000 nm and are useful in the treatment of seasonal and perennial allergic rhinitis and related diseases.
摘要翻译：本发明涉及包含至少一种纳米颗粒H 1 - 组胺受体拮抗剂（例如依巴斯丁或其盐或衍生物）的组合物，其具有改善的溶解速率以提供药物可用性的更快开始。纳米颗粒H1组胺受体拮抗剂颗粒，如依巴斯汀，具有小于约2000nm的有效平均粒度，并且可用于治疗季节性和常年性变应性鼻炎及相关疾病。

10. 发明申请

WO2006110809A2 NANOPARTICULATE LIPASE INHIBITOR FORMULATIONS 审中-公开
标题翻译：纳米脂肪酸抑制剂制剂
公开(公告)号：WO2006110809A2
公开(公告)日：2006-10-19
申请号：PCT/US2006/013639
申请日：2006-04-12
申请人： ELAN PHARMA INTERNATIONAL, LIMITED , LIVERSIDGE, Gary , JENKINS, Scott
发明人： LIVERSIDGE, Gary , JENKINS, Scott
IPC分类号： A61K31/365 , A61K9/14 , A61K47/10 , A61K47/26 , A61K47/32 , A61K47/38
CPC分类号： A61K31/365 , A61K9/145 , A61K9/146 , A61K9/2018 , A61K9/2054
摘要： The invention relates to nanoparticulate lipase inhibitor compositions having improved pharmacokinetic profiles. The nanoparticulate lipase inhibitor compositions have an effective average particle size of less than about 2000 nm and are useful in the treatment of obesity and related diseases.
摘要翻译：本发明涉及具有改善的药代动力学特征的纳米微粒脂肪酶抑制剂组合物。纳米颗粒脂肪酶抑制剂组合物具有小于约2000nm的有效平均粒度，并且可用于治疗肥胖症和相关疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式